Author: Business Wire

U.K. Ophthalmologists Lead in Treatment of Wet AMD Patients with Oraya Therapy Across Europe

NEWARK, Calif. & LIVERPOOL, England–(BUSINESS WIRE)–Oraya Therapeutics Inc. announced today at the Royal College of Ophthalmologists Annual Congress that U.K. ophthalmologists are the leading adopters of Oraya Therapy for the treatment of wet age-related macular degeneration (AMD), two years after the treatment was introduced in the country. Sheffield Teaching Hospitals NHS Foundation Trust alone has treated more than 150 patients in the year since the service was commissioned, with other Nat


Acucela Nominates Shintaro Asako to Its Board of Directors

SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO:4589) (“Acucela” or the “Company”), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, has announced that it has nominated Shintaro Asako to stand for election to the Company’s Board of Directors (the “Board”) at the 2015 Annual Meeting of Shareholders on June 25, 2015 (the “Annual Meeting”) at Acucela’s he


Ocata Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference

MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata”; NASDAQ: OCAT), a leader in the field of regenerative ophthalmology, today announced that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies 2015 Global Healthcare Conference on Monday, June 1, 2015 at 2:00 p.m. EDT in New York City. A live audio webcast of the presentation will be available via the “Investor Relations” page of the Ocata website, www.ocata.com. A repla


R-Tech Ueno: Announcement on Collaborative Development of Therapeutic Agent for Diabetic Retinopathy and Diabetic Macular Edema Utilizing VAP-1 Inhibitor (RTU-1096) with Hokkaido University

TOKYO–(BUSINESS WIRE)–R-Tech Ueno (JASDAQ:4573) R-Tech Ueno, Ltd. has announced plans to conduct collaborative research with a group led by Professor Susumu Ishida and Associate Professor Kousuke Noda of the Department of Ophthalmology, Graduate Scho…

Ocular TherapeutixTM Announces Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication; Reports First Quarter 2015 Financial Results

BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for …

Bruker Secures Major Contract for DE-tector™ Explosives Trace Detector

BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation (NASDAQ: BRKR) today announced that it has secured a contract for the supply of one hundred (100) units of the DE-tector™ explosives trace detection (ETD) system for use at selected airports in Germany, including at the international Frankfurt Airport (FRA). This contract award followed the DE-tector system having successfully met the new European Civil Aviation Conference’s (ECAC) Common Evaluation Process of Security Equipment (CEP) for ai


NovaBay Pharmaceuticals Reports 2015 First Quarter Financial Results and Provides Business Update

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today reported financial results for the three months ended March 31, 2015, and provided a business update. First Quarter 2015 and Recent Operational and Financial Highlights Grew sales of Avenova™ by 112% to $465,000 in the first quarter of 2015 over the fourth quarter of 201


Acucela Announces Publication of Pre-clinical Data for Emixustat Hydrochloride

SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced the publication of pre-clinical data related to the company’s investigational drug candidate, emixustat hydrochloride (emixustat), in the scientific journal PLOS ONE. The published article, “Visual Cycle Modulation as an Approach Towa